AELUMA INC. DL-,0001

Aeluma has signed a letter of intent for planned financing of up to $30 million from the CHIPS and Science Act. The funds are intended to support R&D for its semiconductor manufacturing platform for photonics and will be administered by the U.S. Department of Commerce. Disbursement is subject to due diligence, government approvals and execution of final financing documents; part will be paid upfront, the remainder based on milestones. In connection with the financing, Aeluma would issue shares to the Department of Commerce equivalent to the grant amount. » More on de.investing.com

Aeluma reported Q3 2026 EPS of -$0.04, beating the consensus forecast of -$0.05, while revenue of $1.2M missed expectations of $1.37M. The company recorded a 7.7% decline in annual revenue and reported higher personnel costs and increased R&D spending, but holds $37.8M in cash and has no long‑term liabilities. The stock rose 4.76% in after‑hours trading; management emphasized a strategic focus on quantum dot lasers, InGaAs photodiodes and securing government R&D contracts to fund operations. » More on de.investing.com

Aeluma has entered an equity distribution agreement with Roth Capital as placement agent, alongside Craig‑Hallum, Northland and The Benchmark, enabling the sale of common stock totaling up to $50 million. The offering represents roughly 20% of current market capitalization and is to be sold in tranches through the engaged underwriters on the Nasdaq Capital Market at market prices or otherwise agreed terms; neither Aeluma nor the agents are obligated to sell or buy. The company recently reported a revenue decline and a GAAP net loss in Q2 2026 but maintains full‑year revenue guidance of $4–6 million; additionally, Benchmark reaffirmed a "Buy" rating and Aeluma named Christiane Poblenz VP Materials Operations. » More on de.investing.com